Practical Considerations for Managing Patients on Topical Roflumilast

Sameh Hanna authored a document reviewing safety information for topical roflumilast, a phosphodiesterase-4 inhibitor approved in Canada for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The paper examines the product monograph in light of pharmacokinetic differences between topical and oral formulations, highlighting impacts on adverse effects, drug interactions, and contraindications. It was last updated on May 8, 2026 and is available as a 101.4 KB DOCX file under a CC-BY-4.0 license.

Use Cases

• Reviewing pharmacokinetic differences between topical and oral drug formulations based on the monograph analysis.
• Developing clinical guidance for managing drug-drug interactions based on the discussion of absent formal studies.
• Assessing adverse effect risk profiles for special populations based on the highlighted contraindications.
• Training pharmacists on communicating safety information based on the provided practical guidance.

Strengths

• Focuses on a specific, recently approved topical medication (roflumilast 0.3% cream, 0.15% cream, 0.3% foam).
• Provides a comparative analysis of safety information between topical and oral formulations.
• Includes practical guidance for pharmacists, as stated in the description.
• Is openly licensed (CC-BY-4.0) for reuse.

Limitations

• The dataset is a single 101.4 KB document, indicating a very limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

Sameh Hanna

Freshness

Last updated 2026-05-08 06:00:27; freshness should be verified.

Geography

Canada (based on drug approval references)